Silgan

Q3 FY2026 EarningsQ3 FY26 adjusted EPS of $1.31 beat the $1.25 consensus and reached the top end of guidance, despite a revenue miss ($2.04B vs. $2.10B expected). Growth was driven by double-digit gains in North American pharma dispensing and a 10% increase in Metal Containers Adjusted EBIT. Management raised the full-year FY26 adjusted EPS midpoint to $3.88 (from $3.83) and guided Q4 adjusted EPS to $0.76–$0.86, reflecting strong cost execution amidst muted consumer demand.